Core Viewpoint - Zhaoke Ophthalmology-B (06622) reported a significant decline in revenue and an increase in net loss for the first half of 2025, leading to a drop in stock price by over 8% [1] Financial Performance - The company achieved revenue of 15.803 million HKD, representing a year-on-year decrease of 68.25% [1] - The net loss amounted to 117 million HKD, which is an increase of 53.85% compared to the previous period [1] Reasons for Financial Changes - The increase in net loss is primarily attributed to the absence of one-time licensing income recognized in the previous period under a product licensing agreement [1] - Increased R&D expenses due to the initiation of Phase I and II clinical trials for BRIMOCHOL™ PF and CARBACHOL™ PF, as well as a new Phase III clinical trial for cyclosporine eye gel, offset the impact of a continuous reduction in administrative expenses during the reporting period [1]

收益减少主要是由于公司改变销售策略所致。公司更为着重扩大眼科药物的分销网络，同时重组销售团 队，集中于主要销售地区。因此，整体销售额于报告期内短暂及阶段性下跌。 智通财经APP讯，兆科眼科-B(06622)发布截至2025年6月30日止6个月的中期业绩，该集团取得收益 1580.3万元，同比减少68.25%;净亏损1.17亿元，同比增加53.85%。 公告称，亏损增加主要是由于并无上一期间根据一项产品许可协议确认的一次性许可收入所致。此外， 由于BRIMOCHOL™ PF及CARBACHOL™ PF的第I及第II期临床试验展开，以及环孢素眼用凝胶的新一 轮第III期临床试验开始，导致研发开支增加，继而抵销报告期内行政费用持续减少的部分影响。 ...